May 14 |
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 13 |
Compass Therapeutics GAAP EPS of -$0.08
|
May 13 |
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
|
Apr 25 |
Compass gains FDA Fast Track status for biliary tract cancer candidate
|
Apr 25 |
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
|
Apr 16 |
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
|
Apr 12 |
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
|
Apr 10 |
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
|
Apr 9 |
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Mar 21 |
Compass Therapeutics reports FY results
|